

EDITORIAL

Open Access

The genetic basis of mood and anxiety disorders – changing paradigms

Elisabeth B Binder

Abstract

Family, twin and epidemiologic studies all point to an important genetic contribution to the risk to develop mood and anxiety disorders. While some progress has been made in identifying relevant pathomechanisms for these disorders, candidate based strategies have often yielded controversial findings. Hopes were thus high when genome-wide genetic association studies became available and affordable and allowed a hypothesis-free approach to study genetic risk factors for these disorders. In an unprecedented scientific collaborative effort, large international consortia formed to allow the analysis of these genome-wide association datasets across thousands of cases and controls ([1] and see also <http://www.broadinstitute.org/mpg/ricopili/>). Now that large meta-analyses of genome-wide association studies (GWAS) have been published for bipolar disorder and major depression it has become clear that main effects of common variants are difficult to identify in these disorders, suggesting that additional approaches may be needed to understand the genetic basis of these disorders [2,3].

Several factors need to be considered when evaluating the results of genetic association studies in mood and anxiety disorders.

Phenotype definition

In contrast to other medical disorders, diagnoses for psychiatric disorders are still mostly based on verbal report and observation and not biological measures. It is thus very likely that our symptom-based diagnoses include patients with different primary pathophysiological disturbances and thus likely predisposing genetic variants reducing the power of genetic association studies. In addition, our diagnostic scheme may separate individuals with common genetic risk factors into different categories. For example, it is likely that bipolar disorder patients share genetic susceptibility loci with patients with major depression as well as schizophrenia [4]. Specific symptom categories are shared across mood and anxiety disorders and the use of observational dimensional behavioural phenotypes that cut across diagnostic categories such as psychotic or anxiety symptoms may allow to identify new risk genes for psychiatric disorders [5]. In addition, intermediate phenotype or endophenotypes in mood and anxiety disorders may be a promising

approach, as it is likely that the effect sizes for genetic associations with biological measures are greater than with more remote psychiatric diagnoses. Such phenotypes include but are not limited to neuroimaging, endocrine and neurophysiological measures [6]. In the future, these phenotypes could even include *in vitro* observations on neurons derived from inducible pluripotent stem cells from patient fibroblasts [7].

Functional annotation of associated variants

The published GWAS in mood disorders all highlight that a high number of common variants with small odd ratios likely cumulatively contribute to the risk to suffer from these disorders [8]. While this implies that very large samples will be needed to robustly detect these variants, it also indicates that true associations may not reach genome-wide significance [9]. This has spurred a number of re-analyses of GWAS for psychiatric disorders that explore whether functionally relevant genetic variants may be over-represented among the nominally significant associations and whether this overlap could highlight specific pathways relevant for the disease. To date, investigators have mostly focused on using expression quantitative trait locus (eQTL) analysis as well as methylation quantitative trait locus (mQTL) analysis in different tissues to narrow in on putatively functionally relevant polymorphisms, i.e. variants associated

Correspondence: ebinder@emory.edu
Max-Planck Institute of Psychiatry, Munich Germany and Dept. of Psychiatry and Behavioral Sciences Emory University School of Medicine, Atlanta, GA, USA

with different gene expression or DNA methylation levels [10].

In addition, combining genome-wide protein and gene expression datasets and studies in animal models of mood and anxiety disorders with human genetic studies may also help to identify relevant candidate genes from GWAS. For example, combining GWAS and gene expression studies for bipolar disorder, association signals appear to cluster in discrete regions of the protein–protein interaction network, showing replicated evidence for association for networks involving several interlinked signaling pathways, such as transmission of nerve impulse, Wnt and Notch signaling [11]. Such analyses highlight the importance of investigating such datasets not only on the single gene level but also on the level of functional pathways and new tools allow for stringent testing of the enrichment of signals in specific pathways [12]. Such pathway based analyses also allow better to integrate data from a number of different sources, such as gene expression and proteome datasets, GWAS, copy number variation or rare variant analyses that can highlight overlapping signals from different types of studies [13].

Common vs. rare variants

For schizophrenia and autism but also bipolar disorder it has become increasingly clear that rare variants in addition to common variants contribute to the risk of disease [14]. New technological developments, including next generation sequencing will allow us to study large numbers of patients for the presence of rare functional variants and data from re-sequencing effort of the complete RNA coding sequence (exome) are starting to be published [15]. However, these studies indicate that very large samples, with over 10,000 individuals will be required for sufficient power [16].

Gene x environment interactions

Finally, the environmental risk component is strong in mood and anxiety disorders, especially major depression. A number of candidate gene studies suggest that genes might moderate the effects of environmental risk factors in the absence of main genetic effects [17]. GWAS may profit from the inclusion of environmental exposure as a variable and this could unmask a number of important genetic moderator factors that are not apparent when combining cases and control with different exposure levels to risk environments. However, genome-wide gene x environment studies will require larger sample sizes and will have to deal with the problem of reliably quantifying environmental exposure in studies recruiting from different populations, especially when using retrospective measures. Here, the use of epigenetic investigations

in peripheral blood cells may prove useful as biomarker for environmental exposure [18].

Conclusion

In conclusion, while the results from genetic studies in mood and anxiety disorders may seem disappointing at first sight, a panoply of new analytic strategies and molecular genetic tools is likely to yield significant discoveries in the near future that further our understanding of the pathophysiology of these disorders, some of which will be highlighted in this series.

Received: 22 August 2012 Accepted: 24 August 2012

Published: 1 October 2012

References

1. Sullivan PF: **The psychiatric GWAS consortium: big science comes to psychiatry.** *Neuron* 2010, **68**:182–186.
2. Consortium PG: **A mega-analysis of genome-wide association studies for major depressive disorder.** *Mol Psychiatry* 2012, Apr 3 Epub.
3. Sklar P, Ripke S, Scott LJ, Andreassen OA, Cichon S, Craddock N, et al: **Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4.** *Nat Genet* 2011, **43**:977–983.
4. Schulze TG, Akula N, Breuer R, Steele J, Nalls MA, Singleton AB, et al: **Molecular genetic overlap in bipolar disorder, schizophrenia, and major depressive disorder.** *World J Biol Psychiatry* 2012, Mar 9. [Epub ahead of print]
5. Cardno AG, Rijdsdijk FV, West RM, Gottesman II, Craddock N, Murray RM, et al: **A twin study of schizoaffective mania, schizoaffective depression, and other psychotic syndromes.** *Am J Med Genet B Neuropsychiatr Genet* 2012, **159B**:172–182.
6. Stein JL, Medland SE, Vasquez AA, Hibar DP, Senstad RE, Winkler AM, et al: **Identification of common variants associated with human hippocampal and intracranial volumes.** *Nat Genet* 2012, **44**:552–561.
7. Brennand KJ, Simone A, Tran N, Gage FH: **Modeling psychiatric disorders at the cellular and network levels.** *Mol Psychiatry* 2012, Apr 3. [Epub ahead of print]
8. Wray NR, Pergadia ML, Blackwood DH, Penninx BW, Gordon SD, Nyholt DR, et al: **Genome-wide association study of major depressive disorder: new results, meta-analysis, and lessons learned.** *Mol Psychiatry* 2012, **17**:36–48.
9. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, et al: **Common polygenic variation contributes to risk of schizophrenia and bipolar disorder.** *Nature* 2009, **460**:748–752.
10. Gamazon ER, Badner JA, Cheng L, Zhang C, Zhang D, Cox NJ, et al: **Enrichment of cis-regulatory gene expression SNPs and methylation quantitative trait loci among bipolar disorder susceptibility variants.** *Mol Psychiatry* 2012, Jan 3. [Epub ahead of print]
11. Pedroso I, Lourdasamy A, Rietschel M, Nothen MM, Cichon S, McGuffin P, et al: **Common Genetic Variants and Gene-Expression Changes Associated with Bipolar Disorder Are Over-Represented in Brain Signaling Pathway Genes.** *Biol Psychiatry* 2012 Aug 15, **72**(4):311–317. Epub 2012 Apr 12.
12. Lee PH, O'Dushlaine C, Thomas B, Purcell SM: **INRICH: interval-based enrichment analysis for genome-wide association studies.** *Bioinformatics* 2012, **28**:1797–1799.
13. Ayalew M, Le-Niculescu H, Levey DF, Jain N, Changala B, Patel SD, et al: **Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction.** *Mol Psychiatry* 2012 Sep, **17**(9):887–905.
14. Malhotra D, Sebat J: **CNVs: harbingers of a rare variant revolution in psychiatric genetics.** *Cell* 2012, **148**:1223–1241.
15. Need AC, McEvoy JP, Gennarelli M, Heinzen EL, Ge D, Maia JM, et al: **Exome sequencing followed by large-scale genotyping suggests a limited role for moderately rare risk factors of strong effect in schizophrenia.** *Am J Hum Genet* 2012, **91**:303–312.

16. Kiezun A, Garimella K, Do R, Stitzel NO, Neale BM, McLaren PJ, *et al*: **Exome sequencing and the genetic basis of complex traits.** *Nat Genet* 2012, **44**:623–630.
17. Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE: **Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits.** *Am J Psychiatry* 2010, **167**:509–527.
18. Borghol N, Suderman M, McArdle W, Racine A, Hallett M, Pembrey M, *et al*: **Associations with early-life socio-economic position in adult DNA methylation.** *Int J Epidemiol* 2012, **41**:62–74.

doi:10.1186/2045-5380-2-17

Cite this article as: Binder: The genetic basis of mood and anxiety disorders – changing paradigms. *Biology of Mood & Anxiety Disorders* 2012 **2**:17.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

 **BioMed** Central